Election committee for Vitrolife AB (publ)

The following people have been appointed as members of the election committee for Vitrolife AB for the Annual General Meeting in 2024:

Niels Jacobsen, appointed by William Demant Invest A/S
Patrik Tigerschiöld, appointed by Bure Equity AB
Caroline Sjösten, appointed by Swedbank Robur Fonder AB
Jón Sigurdsson, Chairman of the Board
 

The appointments have been made in accordance with the instructions regarding principles for the appointment of the company election committee which were determined at the Annual General Meeting of Vitrolife AB on April 27, 2023.

The Annual General Meeting of Vitrolife AB (publ) will be held on April 25, 2024 in Gothenburg.

Shareholders who wish to have an item considered at the Annual General Meeting can submit a request to the Board to this effect. Such a request for an item to be considered is to be sent to Vitrolife AB (publ), Att: Chairman of the Board, Box 9080, 400 92 Gothenburg, and must have been received by the Board no later than seven weeks before the Annual General Meeting, or otherwise in such good time that the matter, where necessary, can be included in the notice to attend the Annual General Meeting.

Gothenburg, October 5, 2023
VITROLIFE AB (publ)

This disclosure contains information that Vitrolife AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act (2007:528). The information was submitted for publication, through the agency of the contact person, on 05-10-2023 16:30 CET.

Contact:
Jón Sigurdsson, Chairman of the Board, email: jsigurdsson@ossur.com
Patrik Tolf, CFO, phone +46 31 766 90 21

_____________________________________________________________________________________________________________________________________________________________

Vitrolife Group is a global provider of medical devices and genetic services. Based on science and advanced research capabilities, we develop services and products for personalized genetic information and medical device products. We are supporting our customers by improving their clinical practice and the outcome of the patient’s fertility treatment. Currently, we are approximately 1,100 people worldwide, headquartered in Gothenburg, Sweden. 

Vitrolife Group’s products and services are available in more than 125 countries, through our own presence in more than 25 countries and a network of distributors. We are a sustainable market leader and aim to be the preferred partner to the IVF-clinics by providing superior products and services with the vision to fulfil the dream of having a healthy baby. The Vitrolife AB (publ) share is listed on the Nasdaq Stockholm.
_____________________________________________________________________________________________________________________________________________________________

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg, Sweden. Corporate identity number 556354-3452.Tel: +46 31 721 80 00. Fax: +46 31 721 80 99.
E-mail: info@vitrolife.com. Website: www.vitrolifegroup.com.